1994 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.


Research Output

Immunomodulator use does not prevent first loss of response to anti-tumour necrosis factor alpha therapy in inflammatory bowel disease: long-term outcomes in a real-world cohort

Varma, P., Rajadurai, A., Holt, D. Q., Devonshire, D. A., Desmond, C., Swan, M. P., Nathan, D., Shelton, E., Prideaux, L., Sorrell, C., Rusli, F., Crantock, L. RF., Dev, A., Ratnam, D., Pianko, S. & Moore, G., 1 Jun 2019, In : Internal Medicine Journal. 49, 6, p. 753-760 8 p.

Research output: Contribution to journalArticleResearchpeer-review

1 Citation (Scopus)

Retreatment with elbasvir, grazoprevir, sofosbuvir ± ribavirin is effective for GT3 and GT1/4/6 HCV infection after relapse

Papaluca, T., Sinclair, M., Gow, P., Pianko, S., Sievert, W., Arachchi, N., Cameron, K., Bowden, S., O’Keefe, J., Doyle, J., Stoove, M., Hellard, M., Iser, D. & Thompson, A., 1 Dec 2019, In : Liver International. 39, 12, p. 2285-2290 6 p.

Research output: Contribution to journalArticleResearchpeer-review

2 Citations (Scopus)

Australian recommendations for the management of hepatitis C virus infection: a consensus statement (September 2018)

Hepatitis C Virus Infection Consensus Statement Working Group, 2018, Melbourne VIC Australia: Gastroenterology Society of Australia. 71 p.

Research output: Book/ReportCommissioned ReportOther

Open Access

Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 – final results of the REV1TAL study

Lubel, J., Strasser, S., Stuart, K. A., Dore, G., Thompson, A., Pianko, S., Bollipo, S., Mitchell, J. L., Fragomeli, V., Jones, T., Chivers, S., Gow, P., Iser, D., Levy, M., Tse, E., Gazzola, A., Cheng, W., Nazareth, S., Galhenage, S., Wade, A. & 8 others, Weltman, M., Wigg, A., MacQuillan, G., Sasadeusz, J., George, J., Zekry, A., Roberts, S. K. & the Australian Liver Association Clinical Research Network (ALA CRN), 2017, In : Antiviral Therapy. 22, 8, p. 699-710 12 p.

Research output: Contribution to journalArticleResearchpeer-review

10 Citations (Scopus)

Safety and efficacy of an 8-week regimen of grazoprevir plus ruzasvir plus uprifosbuvir compared with grazoprevir plus elbasvir plus uprifosbuvir in participants without cirrhosis infected with hepatitis C virus genotypes 1, 2, or 3 (C-CREST-1 and C-CREST-2, part A): two randomised, phase 2, open-label trials

Gane, E. J., Pianko, S., Roberts, S. K., Thompson, A. J., Zeuzem, S., Zuckerman, E., Ben-Ari, Z., Foster, G. R., Agarwal, K., Laursen, A. L., Gerstoft, J., Gao, W., Huang, H. C., Fitzgerald, B., Fernsler, D., Li, J. J., Grandhi, A., Liu, H., Su, F. H., Wan, S. & 11 others, Zeng, Z., Chen, H. L., Dutko, F. J., Nguyen, B. Y. T., Wahl, J., Robertson, M. N., Barr, E., Yeh, W. W., Plank, R. M., Butterton, J. R. & Esteban, R., 1 Nov 2017, In : The Lancet Gastroenterology & Hepatology. 2, 11, p. 805-813 9 p.

Research output: Contribution to journalArticleResearchpeer-review

17 Citations (Scopus)